From:  Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies

Active adoptive γδ T-cell immunotherapy clinical trials against hematologic malignancies

ClinicalTrials.gov identifierSponsorDiseaseInterventionPhaseStatus
NCT04696705Institute of Hematology & Blood Diseases HospitalNHL and PTCLEx vivo expanded allogeneic γδ T cellsEarly Phase IRecruiting
NCT05015426H. Lee Moffiff Cancer Center and Research InstituteAMLEx vivo expanded donor γδ T cells post allo-HSCTPhase I/IbRecruiting
NCT04764513Chinese PLA General HospitalAML, ALL, MDS, lymphomaEx vivo expanded donor γδ T cells post allo-HSCTPhase I/IIRecruiting
NCT03533816University of Kanas Medical CenterAML, CML, ALL, MDSEAGD T-cell infusion following haplo-HSCTPhase IRecruiting
NCT05001451GammaDelta Therapeutics LimitedAMLGDX012 infusion–allogeneic Vδ1+ γδ T cellsPhase IRecruiting
NCT04008381Wuhan Union HospitalAMLEx vivo expanded allogeneic γδ T cells from suitable donorPhase IRecruiting
NCT03790072TC BiopharmAMLEx vivo expanded allogeneic γδ T cells from suitable donor (OmnImmune®)Phase ICompleted
NCT04702841PersonGen BioTherapeuticsCD7+ T-cell malignanciesCAR–γδ T cellsEarly Phase IRecruiting
NCT04735471Adicet Bio. Inc.B-cell malignanciesAnti-CD20-CAR-TPhase 1Recruiting
Return to article view

PTCL: peripheral T-cell lymphoma; MDS: myelodysplastic syndrome; CML: chronic myeloid leukemia; EAGD: ex vivo expanded/activated γδ; haplo: haploidentical